NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Not Yet RecruitingPhase 1, Phase 2

Sponsor: University of Minnesota

Conditions: Healthy Volunteers

Interventions: Formulation A, Formulation B, Formulation C

Countries: United States

LD/CD (medications to treat Parkinson's disease) will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. The combination of CD/LD in the inner sachet varies from that in the outer sachet. This allows for sequential release of CD and then LD to mimic a CD pretreatment method which is known to increase LD absorption and prolong its half-life.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult healthy male or female
* Age 18 to 65 years
* Willingness and ability to complete study procedures

Exclusion Criteria:

* medical conditions that require taking medications regularly.

Locations (1)

Minneapolis, Minnesota, United States